Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geny Piro

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic CancerValeria Merz, Camilla Zecchetto, Raffaela Santoro, et al.
Scientific Reports|August 7, 2024
Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot studyMarco Luigetti, Francesca Vitali, Angela Romano, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Oncoimmunology|September 22, 2017
A circulating T<sub>H</sub>2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinomaGeny Piro, Francesca Simionato, Carmine Carbone, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 8, 2025
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic miceCarmine Carbone, Roberto De Luca, Emanuele Puca, et al.
Vaccines|April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung CancerEmanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Journal of Personalized Medicine|April 3, 2021
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will GoRuggero De Maria Marchiano, Gabriele Di Sante, Geny Piro, et al.
Frontiers in Oncology|November 17, 2022
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancerAlessio Stefani, Geny Piro, Francesco Schietroma, et al.
Frontiers in Oncology|January 10, 2022
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old FailuresMiriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2025
The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltrationChiara Cencioni, Silvia Malatesta, Virginia Vigiano Benedetti, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic CancerValeria Merz, Camilla Zecchetto, Raffaela Santoro, et al.
Scientific Reports|August 7, 2024
Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot studyMarco Luigetti, Francesca Vitali, Angela Romano, et al.
Journal for Immunotherapy of Cancer|September 4, 2021
Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancerCarmine Carbone, Geny Piro, Antonio Agostini, et al.
Oncoimmunology|September 22, 2017
A circulating T<sub>H</sub>2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinomaGeny Piro, Francesca Simionato, Carmine Carbone, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 8, 2025
Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic miceCarmine Carbone, Roberto De Luca, Emanuele Puca, et al.
Vaccines|April 23, 2025
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung CancerEmanuele Vita, Federico Monaca, Luca Mastrantoni, et al.
Journal of Personalized Medicine|April 3, 2021
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will GoRuggero De Maria Marchiano, Gabriele Di Sante, Geny Piro, et al.
Frontiers in Oncology|November 17, 2022
Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancerAlessio Stefani, Geny Piro, Francesco Schietroma, et al.
Frontiers in Oncology|January 10, 2022
The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old FailuresMiriam Grazia Ferrara, Alessio Stefani, Sara Pilotto, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2025
The GLP-1R agonist semaglutide reshapes pancreatic cancer associated fibroblasts reducing collagen proline hydroxylation and favoring T lymphocyte infiltrationChiara Cencioni, Silvia Malatesta, Virginia Vigiano Benedetti, et al.
Pageof 6